Center for Neurodegenerative Diseases and the Aging Brain, University of Bari Aldo Moro at Pia Fondazione "Card. G. Panico", Tricase, Italy.
Department of Translational Biomedicine and Neurosciences (DiBraiN), University of Bari Aldo Moro, Bari, Italy.
BMC Geriatr. 2024 Mar 22;24(1):278. doi: 10.1186/s12877-024-04890-w.
Sarcopenia is an age-related clinical syndrome characterized by the progressive loss of muscle mass and muscle strength. It appears to be closely linked to dementia, particularly Alzheimer's disease (AD); however, its prevalence among AD patients remains unclear. In this study, we assessed differences in sarcopenia prevalence between non-demented individuals and AD patients. Moreover, we assessed sex-specific differences in sarcopenia prevalence and explored the diagnostic value of the Muscle Quality Index (MQI) for diagnosing sarcopenia among AD patients.
Cross-sectional study including 145 patients with probable AD and 51 older adults with normal cognition. Sarcopenia was diagnosed according to the criteria of the European Working Group on Sarcopenia in Older People (EWGSOP1 and EWGSOP2) and of the Foundation for the National Institutes of Health (FNIH). The MQI was computed as the ratio of handgrip strength to skeletal muscle mass.
No significant difference in sarcopenia prevalence was observed between AD patients and controls. Prevalence ranged from 3.4 to 23.4% in AD patients and from 2 to 11.8% in controls, depending on diagnostic criteria. Prevalence was higher using EWGSOP1 and decreased using EWGSOP2 and FNIH. Prevalence was higher in males than in females with AD. The MQI was lower in AD patients than in controls (95%CI: - 0.23, - 0.05, p < 0.001), but displayed poor diagnostic accuracy in identifying sarcopenia cases.
AD patients and controls show comparable sarcopenia prevalence. Sarcopenia prevalence is higher in males than females among AD patients and higher when using EWGSOP1 compared to FNIH and EWGSOP2 criteria.
肌少症是一种与年龄相关的临床综合征，其特征为肌肉质量和肌肉力量逐渐丧失。它似乎与痴呆症，尤其是阿尔茨海默病（AD）密切相关；然而，AD 患者中肌少症的患病率尚不清楚。在本研究中，我们评估了非痴呆个体和 AD 患者之间肌少症患病率的差异。此外，我们评估了肌少症患病率的性别差异，并探讨了肌肉质量指数（MQI）在诊断 AD 患者肌少症中的诊断价值。
这是一项横断面研究，纳入了 145 例可能患有 AD 的患者和 51 名认知正常的老年人。根据欧洲老年人肌少症工作组（EWGSOP1 和 EWGSOP2）和美国国立卫生研究院基金会（FNIH）的标准诊断肌少症。MQI 计算为握力与骨骼肌质量的比值。
AD 患者和对照组之间肌少症的患病率无显著差异。根据诊断标准，AD 患者的患病率范围为 3.4%至 23.4%，对照组的患病率范围为 2%至 11.8%。使用 EWGSOP1 时患病率较高，而使用 EWGSOP2 和 FNIH 时患病率降低。AD 患者中男性的患病率高于女性。AD 患者的 MQI 低于对照组（95%CI：-0.23，-0.05，p<0.001），但在识别肌少症病例方面的诊断准确性较差。
AD 患者和对照组的肌少症患病率相当。AD 患者中男性的肌少症患病率高于女性，且与 FNIH 和 EWGSOP2 标准相比，使用 EWGSOP1 时患病率更高。
